AR045685A1 - Piridopirazinas, procedimiento para prepararlas y su uso como inhibidores de quinasas - Google Patents
Piridopirazinas, procedimiento para prepararlas y su uso como inhibidores de quinasasInfo
- Publication number
- AR045685A1 AR045685A1 ARP040101771A ARP040101771A AR045685A1 AR 045685 A1 AR045685 A1 AR 045685A1 AR P040101771 A ARP040101771 A AR P040101771A AR P040101771 A ARP040101771 A AR P040101771A AR 045685 A1 AR045685 A1 AR 045685A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- aryl
- heteroaryl
- cycloalkyl
- heterocyclyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Derivados de pirido[2,3-b]pirazina, su preparación y su uso como medicamentos, en especial para el tratamiento de enfermedades malignas y otras enfermedades basadas en proliferaciones celulares patológicas. Reivindicación 1: Derivados de pirido[2,3-b]pirazina de acuerdo con la fórmula (1) caracterizados porque los substituyentes R1-R3 tienen los siguientes significados: R1 y R2 pueden ser, de modo independiente entre sí: (i) hidrógeno, (ii) hidroxilo, (iii) alquilo, en donde el radical alquilo está saturado y puede estar compuesto por 1 a 8 átomos de carbono, (iv) arilo insubstituido o substituido, en donde el radical arilo puede estar mono o polisubstituido, igual o diferente, con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-cicloalquilo, NH-alquil-heterociclilo, NH-alquil-arilo, NH-alquil-heteroarilo, NH-alquil-NH2, NH-alquil-OH, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-heterociclilo, O-alquil-arilo, O-alquil-heteroarilo, O-alquil-OH, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-arilo, OSO2-heteroarilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, SO2-alquilo, SO2-arilo, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO3H, SO2O-alquilo, SO2O-arilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, y los substituyentes de alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquilarilo y alquil-heteroarilo pueden estar, a su vez, substituidos, (v) heteroarilo insubstituido o substituido, en donde el radical heteroarilo puede estar mono o polisubstituido, igual o diferente, con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-arilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-arilo, O-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-cicloalquilo, OSO2-arilo, OSO2-heteroarilo, C(O)-alquilo, C(O)-arilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)N(alquilo)2, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO3H, SO2O-alquilo, SO2O-arilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, y los substituyentes de alquilo, cicloalquilo, heterociclilo, arilo, heteroarilo, alquil-cicloalquilo, alquil-heterociclilo, alquilarilo y alquil-heteroarilo pueden estar, a su vez, substituidos. R3 puede ser: -C(Y)NR4R5, en donde Y = O, S y R4 y R5 significan de modo independiente entre sí, (i) hidrógeno, (ii) alquilo insubstituido o substituido, en donde el radical alquilo puede estar mono o polisubstituido, igual o diferente,con F, CI, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-cicloalquilo, S-heterociclilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-arilo, O-alquil-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-cicloalquilo, OSO2-arilo, OSO2-heteroarilo, C(O)-alquilo, C(O)-arilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(arilo)2, C(O)N(heteroarilo)2, SO-alquilo, SO-arilo, SO2-alquilo, SO2-arilo, SO2NH2, SO3H, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, (iii) cicloalquilo insubstituido o substituido, en donde el radical cicloalquilo puede estar mono o polisubstituido, igual o diferente, con F, Cl, Br, I, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, OH, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-arilo, O-alquil-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-cicloalquilo, OSO2-arilo, OSO2-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, alquilo o arilo, (iv) heterociclilo insubstituido o substituido, en donde el radical heterociclilo puede estar mono o polisubstituido, igual o diferente,con OH, O-alquilo, O-arilo, NH-alquilo, NH-arilo, alquilo, alquil-arilo o arilo, (v) arilo insubstituido o substituido, en donde el radical arilo puede estar mono o polisubstituido, igual o diferente, con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-cicloalquilo, NH-alquil-heterociclilo, NH-alquil-arilo, NH-alquil-heteroarilo, NH-alquil-NH2, NH-alquil-OH, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-cicloalquilo, S-heterociclilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-heterociclilo, O-alquil-arilo, O-alquil-heteroarilo, O-alquil-OH, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-cicloalquilo, OSO2-arilo, OSO2-heteroarilo, C(O)-alquilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(arilo)2, C(O)N(heteroarilo)2, SO-alquilo, SO-arilo, SO2-alquilo, SO2-arilo, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO3H, SO2O-alquilo, SO2O-arilo, SO2O-heteroarilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, (vi) heteroarilo insubstituido o substituido, en donde el radical heteroarilo puede estar mono o polisubstituido, igual o diferente, con F, Cl, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-arilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO2-arilo, OSO2-heteroarilo, C(O)-alquilo, C(O)-arilo, C(O)-heteroarilo, CO2H, CO2-alquilo, CO2-cicloalquilo, CO2-heterociclilo, CO2-arilo, CO2-heteroarilo, CO2-alquil-cicloalquilo, CO2-alquil-heterociclilo, CO2-alquil-arilo, CO2-alquil-heteroarilo, C(O)-NH2, C(O)NH-alquilo, C(O)NH-cicloalquilo, C(O)NH-heterociclilo, C(O)NH-arilo, C(O)NH-heteroarilo, C(O)NH-alquil-cicloalquilo, C(O)NH-alquil-heterociclilo, C(O)NH-alquil-arilo, C(O)NH-alquil-heteroarilo, C(O)N(alquilo)2, C(O)N(alquilo)2, C(O)N(cicloalquilo)2, C(O)N(arilo)2, C(O)N(heteroarilo)2, SO2-alquilo, SO2-arilo, SO2NH2, SO2NH-alquilo, SO2NH-arilo, SO2NH-heteroarilo, SO3H, SO2O-alquilo, SO2O-arilo, SO2O-heteroarilo, alquilo, cicloalquilo, heterociclilo, arilo o heteroarilo, (vii) o R4 y R5 significan juntos cicloalquilo o heterociclilo, -C(Y)NR6R7, en donde Y = NH y R6 y R7 significan de modo independiente entre sí, (i) hidrógeno, (ii) alquilo insubstituido o substituido, en donde el radical alquilo puede estar mono o polisubstituido, igual o diferente, con F, CI, Br, I, CF3, CN, NH2, NH-alquilo, NH-cicloalquilo, NH-heterociclilo, NH-arilo, NH-heteroarilo, NH-alquil-arilo, NH-alquil-heteroarilo, N(alquilo)2, NHC(O)-alquilo, NHC(O)-cicloalquilo, NHC(O)-heterociclilo, NHC(O)-arilo, NHC(O)-heteroarilo, NHSO2-alquilo, NHSO2-cicloalquilo, NHSO2-arilo, NHSO2-heteroarilo, NO2, SH, S-alquilo, S-cicloalquilo, S-heterociclilo, S-arilo, S-heteroarilo, OH, OCF3, O-alquilo, O-cicloalquilo, O-heterociclilo, O-arilo, O-heteroarilo, O-alquil-cicloalquilo, O-alquil-arilo, O-alquil-heteroarilo, OC(O)-alquilo, OC(O)-cicloalquilo, OC(O)-heterociclilo, OC(O)-arilo, OC(O)-heteroarilo, OSO2-alquilo, OSO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10323345A DE10323345A1 (de) | 2003-05-23 | 2003-05-23 | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
Publications (1)
Publication Number | Publication Date |
---|---|
AR045685A1 true AR045685A1 (es) | 2005-11-09 |
Family
ID=33441206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101771A AR045685A1 (es) | 2003-05-23 | 2004-05-21 | Piridopirazinas, procedimiento para prepararlas y su uso como inhibidores de quinasas |
Country Status (17)
Country | Link |
---|---|
US (3) | US7323468B2 (es) |
EP (1) | EP1628976A1 (es) |
JP (1) | JP2007500195A (es) |
KR (1) | KR20060015283A (es) |
CN (2) | CN1795195B (es) |
AR (1) | AR045685A1 (es) |
AU (1) | AU2004240746B2 (es) |
BR (1) | BRPI0410632A (es) |
CA (1) | CA2524948A1 (es) |
DE (1) | DE10323345A1 (es) |
MX (1) | MXPA05012592A (es) |
NO (1) | NO20056030L (es) |
RS (2) | RS51906B (es) |
RU (1) | RU2005140378A (es) |
TW (1) | TW200504062A (es) |
WO (1) | WO2004104002A1 (es) |
ZA (2) | ZA200508872B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004022383A1 (de) * | 2004-05-06 | 2005-12-01 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen |
AU2004240747B2 (en) * | 2003-05-23 | 2008-01-03 | Zentaris Gmbh | Novel pyridopyrazines and use thereof as kinase modulators |
DE10323345A1 (de) * | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
US20100132790A1 (en) * | 2005-05-09 | 2010-06-03 | Solaris Nanosciences, Inc. | Rechargeable Dye Sensitized Solar Cell |
CN101356173B (zh) * | 2005-11-11 | 2012-10-31 | 阿特纳赞塔里斯有限公司 | 新的吡啶并吡嗪和它们作为激酶调节剂的用途 |
WO2007054556A1 (de) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
EP1785423A1 (de) * | 2005-11-11 | 2007-05-16 | Zentaris GmbH | Neue Pyridopyrazine und deren Verwendung als Modulatoren von Kinasen |
EP1790342A1 (de) * | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
EP1990342A1 (en) * | 2007-05-10 | 2008-11-12 | AEterna Zentaris GmbH | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2508184A1 (en) | 2011-04-06 | 2012-10-10 | Æterna Zentaris GmbH | Pyridopyrazine derivatives and their use |
WO2012167423A1 (en) * | 2011-06-08 | 2012-12-13 | Hutchison Medipharma Limited | Substituted pyridopyrazines as novel syk inhibitors |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
RU2715893C2 (ru) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
HRP20220012T1 (hr) | 2015-09-23 | 2022-04-01 | Janssen Pharmaceutica Nv | Bi-heteroaril supstituirani 1,4-benzodiazepini i njihova upotreba za liječenje raka |
MX2018003563A (es) | 2015-09-23 | 2018-06-18 | Janssen Pharmaceutica Nv | Nuevos compuestos. |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5053394A (es) | 1973-09-20 | 1975-05-12 | ||
GB9413975D0 (en) | 1994-07-11 | 1994-08-31 | Fujisawa Pharmaceutical Co | New heterobicyclic derivatives |
TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
US5700823A (en) | 1994-01-07 | 1997-12-23 | Sugen, Inc. | Treatment of platelet derived growth factor related disorders such as cancers |
UA71555C2 (en) * | 1997-10-06 | 2004-12-15 | Zentaris Gmbh | Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives |
BR0212510A (pt) * | 2001-09-14 | 2004-08-24 | Methylgene Inc | Inibidor de histona desacetilase, composto e composição |
US7223738B2 (en) | 2002-04-08 | 2007-05-29 | Merck & Co., Inc. | Inhibitors of Akt activity |
US20060142178A1 (en) | 2002-04-08 | 2006-06-29 | Barnett Stanley F | Method of treating cancer |
JP4451136B2 (ja) | 2002-04-08 | 2010-04-14 | メルク エンド カムパニー インコーポレーテッド | Akt活性阻害薬 |
JP4903997B2 (ja) | 2002-07-02 | 2012-03-28 | サザン リサーチ インスティチュート | FtsZの阻害剤およびそれらの用途 |
KR20120032574A (ko) | 2002-10-03 | 2012-04-05 | 탈자진 인코포레이티드 | 혈관항상성 유지제 및 그의 사용 방법 |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
AU2003270701B2 (en) * | 2002-10-31 | 2009-11-12 | Amgen Inc. | Antiinflammation agents |
DE10323345A1 (de) | 2003-05-23 | 2004-12-16 | Zentaris Gmbh | Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren |
AU2004259269A1 (en) | 2003-07-18 | 2005-02-03 | Basf Aktiengesellschaft | Aryl-condensed 3-arylpyridine compounds and use thereof for controlling pathogenic fungi |
WO2005056825A1 (en) | 2003-12-05 | 2005-06-23 | Board Of Regents, The University Of Texas System | Screening for modulators of mekk2 and mekk3 |
US7572914B2 (en) | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
DE102004017932A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
JP4903133B2 (ja) | 2004-04-30 | 2012-03-28 | ジェネンテック,インコーポレイティド | ヘッジホッグシグナル伝達のキノキサリン阻害剤 |
GB0413953D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
GB0413955D0 (en) | 2004-06-22 | 2004-07-28 | Syngenta Participations Ag | Chemical compounds |
TW200621251A (en) | 2004-10-12 | 2006-07-01 | Neurogen Corp | Substituted biaryl quinolin-4-ylamine analogues |
US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
JP2006137723A (ja) | 2004-11-15 | 2006-06-01 | Kyowa Hakko Kogyo Co Ltd | スルホンアミド誘導体 |
WO2006059103A2 (en) | 2004-12-03 | 2006-06-08 | Peakdale Molecular Limited | Pyridine based compounds useful as intermediates for pharmaceutical or agricultural end-products |
US20070293456A9 (en) | 2004-12-30 | 2007-12-20 | Anthony Hayford | Method for the synthesis of 3-substituted indolizine and benzoindolizine compounds |
CA2592900A1 (en) | 2005-01-03 | 2006-07-13 | Myriad Genetics Inc. | Nitrogen containing bicyclic compounds and therapeutical use thereof |
WO2006076646A2 (en) | 2005-01-14 | 2006-07-20 | Neurogen Corporation | Heteroaryl substituted quinolin-4-ylamine analogues |
US7709472B2 (en) | 2005-01-25 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
JP2008528588A (ja) | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
WO2006081264A1 (en) | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
CA2594998A1 (en) | 2005-01-25 | 2006-08-03 | Neurogen Corporation | Substituted pyridazinyl-and pyrimidinyl-quinolin-4-ylamine analogues |
JP2008528586A (ja) | 2005-01-25 | 2008-07-31 | グラクソ グループ リミテッド | 抗菌剤 |
US20070032493A1 (en) | 2005-05-26 | 2007-02-08 | Synta Pharmaceuticals Corp. | Method for treating B cell regulated autoimmune disorders |
WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
-
2003
- 2003-05-23 DE DE10323345A patent/DE10323345A1/de not_active Withdrawn
-
2004
- 2004-05-19 MX MXPA05012592A patent/MXPA05012592A/es active IP Right Grant
- 2004-05-19 WO PCT/EP2004/005379 patent/WO2004104002A1/de not_active Application Discontinuation
- 2004-05-19 CA CA002524948A patent/CA2524948A1/en not_active Abandoned
- 2004-05-19 RU RU2005140378/04A patent/RU2005140378A/ru not_active Application Discontinuation
- 2004-05-19 CN CN2004800142149A patent/CN1795195B/zh not_active Expired - Fee Related
- 2004-05-19 JP JP2006529871A patent/JP2007500195A/ja not_active Withdrawn
- 2004-05-19 EP EP04733782A patent/EP1628976A1/de not_active Withdrawn
- 2004-05-19 RS YU20050876A patent/RS51906B/sr unknown
- 2004-05-19 CN CNA2004800142045A patent/CN1795194A/zh active Pending
- 2004-05-19 KR KR1020057022237A patent/KR20060015283A/ko not_active Application Discontinuation
- 2004-05-19 BR BRPI0410632-6A patent/BRPI0410632A/pt not_active IP Right Cessation
- 2004-05-19 RS YUP-2005/0864A patent/RS20050864A/sr unknown
- 2004-05-19 AU AU2004240746A patent/AU2004240746B2/en not_active Ceased
- 2004-05-20 TW TW093114323A patent/TW200504062A/zh unknown
- 2004-05-21 AR ARP040101771A patent/AR045685A1/es not_active Application Discontinuation
- 2004-05-21 US US10/851,966 patent/US7323468B2/en not_active Expired - Fee Related
-
2005
- 2005-02-11 ZA ZA200508872A patent/ZA200508872B/en unknown
- 2005-10-25 ZA ZA200508633A patent/ZA200508633B/en unknown
- 2005-12-19 NO NO20056030A patent/NO20056030L/no unknown
-
2007
- 2007-07-05 US US11/825,200 patent/US8193186B2/en not_active Expired - Fee Related
- 2007-11-12 US US11/985,031 patent/US20080113991A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004104002A1 (de) | 2004-12-02 |
CA2524948A1 (en) | 2004-12-02 |
US20050032803A1 (en) | 2005-02-10 |
ZA200508633B (en) | 2006-07-26 |
US7323468B2 (en) | 2008-01-29 |
AU2004240746B2 (en) | 2007-05-31 |
RU2005140378A (ru) | 2007-06-27 |
JP2007500195A (ja) | 2007-01-11 |
US8193186B2 (en) | 2012-06-05 |
US20080113991A1 (en) | 2008-05-15 |
AU2004240746A1 (en) | 2004-12-02 |
RS20050864A (en) | 2008-04-04 |
CN1795195B (zh) | 2010-04-21 |
DE10323345A1 (de) | 2004-12-16 |
EP1628976A1 (de) | 2006-03-01 |
BRPI0410632A (pt) | 2006-06-13 |
CN1795195A (zh) | 2006-06-28 |
US20070275972A1 (en) | 2007-11-29 |
ZA200508872B (en) | 2006-07-26 |
NO20056030L (no) | 2006-02-15 |
RS20050876A (en) | 2008-04-04 |
MXPA05012592A (es) | 2006-02-08 |
TW200504062A (en) | 2005-02-01 |
CN1795194A (zh) | 2006-06-28 |
RS51906B (sr) | 2012-02-29 |
KR20060015283A (ko) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR045685A1 (es) | Piridopirazinas, procedimiento para prepararlas y su uso como inhibidores de quinasas | |
AR045686A1 (es) | Derivados de pirido[2,3-b]pirazinas, y su uso como moduladores de quinasas | |
AR056216A1 (es) | Derivados de piridopirazina y su uso | |
KR880007535A (ko) | 설포닐우레아 화합물 | |
ES2334851T3 (es) | Material estructural poroso metalo-organico a base de pirroles y piridinonas. | |
ES2552515T3 (es) | Derivados de piridopirazina y su uso | |
TR199802282T2 (xx) | Karbolin t�revleri. | |
Box et al. | Paramagnetic Absorption of L‐Cystine Dihydrochloride Irradiated at Low Temperature | |
Wu et al. | The design of CMOS self-powered 256-pixel implantable chip with on-chip photovoltaic cells and active pixel sensors for subretinal prostheses | |
DE69028930D1 (de) | 1,2-Ethandiolderivate und ihre Salze, Verfahren zu ihrer Herstellung und sie enthaltende gehirnfunktionsverbessernde Mittel | |
INAGAKI et al. | Platinum complexes of diaminocarboxylates and their ethyl ester derivatives: antitumor activity and interaction with deoxyribonucleic acid | |
El-Shazly et al. | Coordination chemistry of benzothiazole derivatives. 2-mercaptobenzothiazole and 2-(o-hydroxyphenyl) benzothiazole complexes with Cu (II), Ni (II) and Co (II) | |
ATE137240T1 (de) | Tricyclische thiazol- und oxazol-derivate mit antiviraler wirkung | |
Sukul et al. | A water-soluble metal–organic complex array as a multinuclear heterometallic peptide amphiphile that shows unconventional anion dependency in its self-assembly | |
ES2163029T3 (es) | Procedimiento para preparar n-fosfonometilglicina. | |
Martín | Miguel de Unamuno y Giacomo Leopardi | |
Schmitt | Additional records of the occurrence of the fresh-water jelly-fish | |
Gangjee et al. | Diazoketone and chloromethylketone analogs of methotrexate as potential antitumor agents | |
Singh et al. | Electronic Structure–Activity Relationships of Antibacterial Acridines | |
RUST et al. | Coronal magnetic fields above active regions(Coronal magnetic fields above slowly changing active regions) | |
ES430786A1 (es) | Procedimiento para la obtencion de esteres de acidos tria- zolotiazol-fosforicos, -tionodosfoticos, -fosfonicos y tio- nodosfonicos, de efecto insecticida y acaricida. | |
Smit | Two new and rare Arrenurus-species from The Netherlands (Acari: Hydrachnellae) | |
USD226577S (en) | Pendant or the like | |
Tribute | Professor Vladimir I. Minkin | |
Raymond et al. | Examples of p-adic transformation groups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |